{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T09:51:41Z","timestamp":1792057901073,"version":"4.4.0"},"publisher-location":"Chichester, UK","reference-count":69,"publisher":"John Wiley & Sons, Ltd","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.1002\/14651858.cd003474.pub2","type":"reference-entry","created":{"date-parts":[[2005,7,4]],"date-time":"2005-07-04T17:18:45Z","timestamp":1120497525000},"source":"Crossref","is-referenced-by-count":157,"title":["Bisphosphonates for breast cancer"],"prefix":"10.1002","author":[{"given":"Nick","family":"Pavlakis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert L","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin R","family":"Stockler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2005,7,20]]},"reference":[{"issue":"6","key":"10.1002\/14651858.CD003474.pub2-BIB1|cit1","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1200\/JCO.1998.16.6.2038","article-title":"Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate.","volume":"16","author":"Hortobagyi","year":"1998","journal-title":"Journal of Clinical Oncology"},{"issue":"24","key":"10.1002\/14651858.CD003474.pub2-BIB2|cit2","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1056\/NEJM199612123352401","article-title":"Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases.","volume":"335","author":"Hortobagyi","year":"1996","journal-title":"The New England Journal of Medicine"},{"issue":"5","key":"10.1002\/14651858.CD003474.pub2-BIB3|cit3","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1002\/(SICI)1097-0142(20000301)88:5<1082::AID-CNCR20>3.0.CO;2-Z","article-title":"Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases","volume":"88","author":"Lipton","year":"2000","journal-title":"Cancer"},{"issue":"3","key":"10.1002\/14651858.CD003474.pub2-BIB4|cit4","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1200\/JCO.1999.17.3.846","article-title":"Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: A randomized, placebo-controlled trial.","volume":"17","author":"Theriault","year":"1999","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD003474.pub2-BIB5|cit5","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1093\/annonc\/mdg367","article-title":"Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases","volume":"14","author":"Body","year":"2003","journal-title":"Annals of Oncology"},{"key":"10.1002\/14651858.CD003474.pub2-BIB6|cit6","series-title":"Proceedings Annual Meeting American Society Clinical Oncology","first-page":"abstract 2222","article-title":"Double-blind Placebo-Controlled Trial of Intravenous Ibandronate in Breast Cancet Metastatic to Bone","author":"Body","year":"1999"},{"key":"10.1002\/14651858.CD003474.pub2-BIB7|cit7","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1016\/j.ejca.2004.03.025","article-title":"Improved quality of life after long-term treatment with the bisphosphonate ibandronate in patients with metastatic bone disease due to breast cancer","volume":"40","author":"Diel","year":"2004","journal-title":"European Journal of Cancer"},{"key":"10.1002\/14651858.CD003474.pub2-BIB8|cit8","series-title":"Proceedings of the 15th Annual MASCC Meeting","article-title":"Long-term treatment with intravenous ibandronate does not affect renal function in breast cancer patients with metastatic bone disease.","author":"Lyubimova","year":"2003"},{"key":"10.1002\/14651858.CD003474.pub2-BIB9|cit9","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.pain.2004.07.011","article-title":"Oral ibandronate improves bone pain and preserves quality of life in patients with skeletal metastases due to breast cancer","volume":"111","author":"Body","year":"2004","journal-title":"Pain"},{"key":"10.1002\/14651858.CD003474.pub2-BIB10|cit10","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1038\/sj.bjc.6601663","article-title":"Oral ibandronate reduces the risk of skeletal complications in breat cancer patients with metastatic bone disease: results from two randomised, placebo-controlled phase III studies","volume":"90","author":"Body","year":"2004","journal-title":"British Journal of Cancer"},{"issue":"Supp .7","key":"10.1002\/14651858.CD003474.pub2-BIB11|cit11","first-page":"S41","article-title":"Delayed progression of bone metastases with pamodronate therapy in breast cancer patients: A randomized , multicenter phase III trial","volume":"5","author":"Conte","year":"1994","journal-title":"Annals of Oncology"},{"issue":"9","key":"10.1002\/14651858.CD003474.pub2-BIB12|cit12","doi-asserted-by":"crossref","first-page":"2552","DOI":"10.1200\/JCO.1996.14.9.2552","article-title":"Delay in progression of bone metastases in breast cancer patients treated with intravenous pamidronate: Results from a multinational randomized controlled trial","volume":"14","author":"Conte","year":"1996","journal-title":"Jounal of Clinical Oncology"},{"issue":"6","key":"10.1002\/14651858.CD003474.pub2-BIB13|cit13","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1056\/NEJM199808063390601","article-title":"Reduction in new metastases in breast cancer with adjuvant clodronate treatment","volume":"339","author":"Diel","year":"1998","journal-title":"The New England Journal Of Medicine"},{"key":"10.1002\/14651858.CD003474.pub2-BIB14|cit14","series-title":"Journal of Clinical Oncology 22(14S): 529","article-title":"Adjuvant clodronate treatment improves the overall survival of primary breast cancer patients with micrometastases to bone marrow - a longtime follow-up.","author":"Jaschke","year":"2004"},{"key":"10.1002\/14651858.CD003474.pub2-BIB15|cit15","series-title":"Proc Annu Meet Am Soc Clin Oncol","first-page":"Abstract 488","article-title":"Continual oral versus intravenous interval therapy with bisphosphonates in patients with breast cancer and bone metastases","author":"Diel","year":"1999"},{"key":"10.1002\/14651858.CD003474.pub2-BIB16|cit16","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/S0140-6736(83)92755-1","article-title":"Long-term controlled trial with diphosphonate in aptients with osteolytic bone metastases","volume":"1","author":"Elomaa","year":"1983","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD003474.pub2-BIB17|cit17","first-page":"111","article-title":"Clodronate for osteolytic metastases due to breast cancer","volume":"42","author":"Elomaa","year":"1988","journal-title":"Biomed. & Parmacother."},{"issue":"Supp 1","key":"10.1002\/14651858.CD003474.pub2-BIB18|cit18","first-page":"S53","article-title":"Treatment of skeletal disease in breast cancer: A controlled clodronate trial","volume":"8","author":"Elomma","year":"1987","journal-title":"Bone"},{"key":"10.1002\/14651858.CD003474.pub2-BIB19|cit19","first-page":"3383","article-title":"Efficacy of pamidronate in breast cancer with bone metastases: A randomized , double-blind placebo-controlled multicenter study","volume":"19","author":"Hultborn","year":"1999","journal-title":"Anticancer Research"},{"issue":"6","key":"10.1002\/14651858.CD003474.pub2-BIB20|cit20","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/S8756-3282(96)00285-2","article-title":"Clodronate decreases the frequency of skeletal metastases in women with breast cancer","volume":"19","author":"Kanis","year":"1996","journal-title":"Bone"},{"issue":"15","key":"10.1002\/14651858.CD003474.pub2-BIB21|cit21","doi-asserted-by":"crossref","first-page":"3314","DOI":"10.1200\/JCO.2005.05.116","article-title":"Zolendronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: A randomized, Placebo-controlled Trial.","volume":"23","author":"Kohno","year":"2005","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD003474.pub2-BIB22|cit22","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1046\/j.1365-2796.1999.00507.x","article-title":"Oral clodronate in breast cancer patients with bone metastases: a randomized study","volume":"246","author":"Kristensen","year":"1999","journal-title":"Jounal of Internal Medicine"},{"issue":"3","key":"10.1002\/14651858.CD003474.pub2-BIB23|cit23","first-page":"177","article-title":"Adjuvant clodronate therapy in patients with locally advanced breast cancer - long term results of a double blind randomized trial","volume":"47","author":"Mardiak","year":"2000","journal-title":"Neoplasma"},{"key":"10.1002\/14651858.CD003474.pub2-BIB24|cit24","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1159\/000226904","article-title":"Controlled clinical study on the use of dichloromethylene diphosphonate in patients with breast carcinoma metastasizing to the skeleton","volume":"48","author":"Martoni","year":"1991","journal-title":"Oncology"},{"key":"10.1002\/14651858.CD003474.pub2-BIB25|cit25","unstructured":"Paterson AHG Kanis JA Powles TJ McCloskey EV Archabault WT Kurman MR A re-analysis of a trial of clodronate in patients with breast cancer and bone metastases Anthra Pharmaceuticals"},{"issue":"1","key":"10.1002\/14651858.CD003474.pub2-BIB26|cit26","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1200\/JCO.1993.11.1.59","article-title":"Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer","volume":"11","author":"Paterson","year":"1993","journal-title":"Journal of Clinical Oncology"},{"issue":"9","key":"10.1002\/14651858.CD003474.pub2-BIB27|cit27","doi-asserted-by":"crossref","first-page":"661","DOI":"10.2165\/00002018-200326090-00005","article-title":"Extended safety profile of oral clodronate after long-term use in primary breast cancer patients.","volume":"26","author":"Atula","year":"2003","journal-title":"Drug safety"},{"key":"10.1002\/14651858.CD003474.pub2-BIB28|cit28","series-title":"Journal of Clinical Oncology","first-page":"Abstract 528","article-title":"Oral clondronate for the adjuvant treatment of operable breast cancer: Results of a randomized, double-blind, placebo-controlled multicenter trial","author":"Powles","year":"2004"},{"issue":"15","key":"10.1002\/14651858.CD003474.pub2-BIB29|cit29","doi-asserted-by":"crossref","first-page":"3219","DOI":"10.1200\/JCO.2002.11.080","article-title":"Randomized, Placebo-Controlled Trial of Clodronate in Patients with Primary Operable Breast Cancer","volume":"20","author":"Trevor","year":"2002","journal-title":"Journal of Clinical Oncology"},{"issue":"8","key":"10.1002\/14651858.CD003474.pub2-BIB30|cit30","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1002\/cncr.11701","article-title":"Long term efficacy and safety of zolendronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma","volume":"98","author":"Rosen","year":"2003","journal-title":"Cancer"},{"issue":"1","key":"10.1002\/14651858.CD003474.pub2-BIB31|cit31","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1002\/cncr.11892","article-title":"Zolendronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion.","volume":"100","author":"Rosen","year":"2004","journal-title":"Cancer"},{"issue":"5","key":"10.1002\/14651858.CD003474.pub2-BIB32|cit32","first-page":"377","article-title":"Zolendronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or psteolytic lesions of multiple myeloma: A Phase III, bouble-blind, comparative trial.","volume":"7","author":"Rosen","year":"2001","journal-title":"Cancer"},{"issue":"1","key":"10.1002\/14651858.CD003474.pub2-BIB33|cit33","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1200\/JCO.2001.19.1.10","article-title":"Adjuvant clodronate treatment does not reduce the frequency of skeletal metastases in node-postive breast cancer patients: 5 year results of a randomized controlled study","volume":"19","author":"Saarto","year":"2001","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD003474.pub2-BIB34|cit34","first-page":"1047","article-title":"Ten-year Follow-up of a Randomized Controlled Trial of Adjuvant Clodronate Treatment in Node-positive Breast Cancer Patients","volume":"84","author":"Saarto","year":"2004","journal-title":"Acta Oncologica"},{"key":"10.1002\/14651858.CD003474.pub2-BIB35|cit35","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1093\/annonc\/mdh173","article-title":"Oral ibandronate for the treatment of metastatic bone disease in breast cancer: efficacy and safety results from a randomized, double-blind, placebo-controlled trial","volume":"15","author":"Tripathy","year":"2004","journal-title":"Annals of Oncology"},{"issue":"7","key":"10.1002\/14651858.CD003474.pub2-BIB36|cit36","first-page":"701","article-title":"Double-blinded controlled study comparing clodronate versus placebo in patients with breast cancer bone metastases","volume":"88","author":"Tubiana-Hulin","year":"2001","journal-title":"Bulletin du Cancer"},{"key":"10.1002\/14651858.CD003474.pub2-BIB37|cit37","first-page":"73","article-title":"Effect of long-term bisphosponate treatment on morbidity due to bone metastases in breast cancer patients","volume-title":"Recent results in Cancer Research","volume":"116","author":"Cleton","year":"1989"},{"issue":"3","key":"10.1002\/14651858.CD003474.pub2-BIB38|cit38","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1200\/JCO.1993.11.3.491","article-title":"Palliative pamidronate treatment in patients with bone metastases from breast cancer","volume":"11","author":"Holten-Vaerzantvoort","year":"1993","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD003474.pub2-BIB39|cit39","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/S0140-6736(87)92555-4","article-title":"Reduced morbidity from skeletal metastases in breast cancer patients during long-term bisphophonate (APD) treatment","volume":"ii","author":"Holten-Verzantvoort","year":"1987","journal-title":"Lancet"},{"issue":"5","key":"10.1002\/14651858.CD003474.pub2-BIB40|cit40","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/0277-5379(91)90212-V","article-title":"The effect of Supportive Pamidronate Treatment on Aspects of Quality of Life of Patients with Advanced Breast Cancer","volume":"27","author":"Holten-Verzantvoort","year":"1991","journal-title":"European Journal of Cancer"},{"issue":"3","key":"10.1002\/14651858.CD003474.pub2-BIB41|cit41","first-page":"450","article-title":"Does supportive pamidronate treatment prevent or delay the first manifestations of bone metastases in breast cancer patients?","volume":"32A","author":"van","year":"1996","journal-title":"European Journal of Cancer"},{"issue":"7","key":"10.1002\/14651858.CD003474.pub2-BIB42|cit42","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1002\/1097-0142(20010401)91:7<1191::AID-CNCR1119>3.0.CO;2-0","article-title":"Zolendronic Acid Reduces Skeleta-Related Events in Patients with Osteolytic Metastases: A double-blind, randomized dose-response study","volume":"91","author":"Berenson","year":"2001","journal-title":"Cancer"},{"issue":"6","key":"10.1002\/14651858.CD003474.pub2-BIB43|cit43","doi-asserted-by":"crossref","first-page":"3209","DOI":"10.1210\/jc.2004-1444","article-title":"Pamidronate in the prevention of chemotherapy-induced bone loss in premenopausal women with breast cancer: a randomized controlled trial","volume":"90","author":"Fuleihan","year":"2005","journal-title":"Journal of Endocrinology and Metabolism"},{"issue":"10","key":"10.1002\/14651858.CD003474.pub2-BIB44|cit44","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1023\/A:1012506426440","article-title":"Comparison of the effects of intravenous pamidronate and oral clodronate on symptoms and bone resorption in patients with metastatic bone disease.","volume":"12(10):1433-8,","author":"Jagdev","year":"2001","journal-title":"Annals of Oncology"},{"key":"10.1002\/14651858.CD003474.pub2-BIB45|cit45","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s10549-004-3722-5","article-title":"Clondronate treatment influences MMP-2 associated outcome in node postive breast cancer","volume":"90","author":"Leppa","year":"2005","journal-title":"Breast Cancer Research and Treatment"},{"key":"10.1002\/14651858.CD003474.pub2-BIB46|cit46","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1007\/s00223-004-0262-2","article-title":"Three-Year Oral Clodronate Treatment Does Not Impair Mineralization of Newly Formed Bone -- A Histomorphometric Study","volume":"77","author":"Saarto","year":"2005","journal-title":"Calcified Tissue International"},{"key":"10.1002\/14651858.CD003474.pub2-BIB47|cit47","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/0002-9343(83)90958-0","article-title":"Effects if dichloromethylene Diphosphonate in Women with Breast Carcinoma Metastatic to the Skeleton","volume":"74","author":"Siris","year":"1983","journal-title":"The American Journal of Medicine"},{"key":"10.1002\/14651858.CD003474.pub2-BIB48|cit48","first-page":"2373","article-title":"Long-term impact of chemotherapy-induced ovarian failure on bone mineral density (BMD) in premenopausal breast cancer patients. The effect of adjuvant clodronate treatment.","volume":"37","author":"Vehmanen","year":"2001","journal-title":"Breast Cancer Research and Treatment"},{"key":"10.1002\/14651858.CD003474.pub2-BIB49|cit49","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1023\/B:BREA.0000041624.00665.4e","article-title":"Short-term intermittent intravenous clodronate in the prevention of bone loss related to chemotherapy-induced ovarian failure","volume":"87","author":"Vehmanen","year":"2004","journal-title":"Breast Cancer Research and Treatment"},{"issue":"2","key":"10.1002\/14651858.CD003474.pub2-BIB50|cit50","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1097\/01.mlr.0000108746.69256.45","article-title":"Health-Related Quality of Life Among Patients with Breat Cancer Receiving Zolendronic Acid or Pamidronate Disodium for Metastatic Bone Lesions","volume":"42","author":"Weinfurt","year":"2004","journal-title":"Medical Care"},{"key":"10.1002\/14651858.CD003474.pub2-BIB51|cit51","unstructured":"Phase III Randomized study of adjuvant chemotherapy and\/or hormonal therapy with or without zolendronate in women with stage II or III breast cancer. Ongoing study"},{"key":"10.1002\/14651858.CD003474.pub2-BIB52|cit52","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1214\/aos\/1176345976","article-title":"Cox's regression model for counting processes: a large sample study","volume":"10","author":"Anderson","year":"1982","journal-title":"Ann Stat"},{"issue":"3","key":"10.1002\/14651858.CD003474.pub2-BIB53|cit53","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1200\/JCO.1998.16.3.1218","article-title":"Should bisphosphonates be part of the standard therapy of patients with mutliple myeloma or bone metastases from other cancers? An evidence-based review","volume":"16","author":"Bloomfield","year":"1998","journal-title":"Journal of Clinical Oncology"},{"issue":"12","key":"10.1002\/14651858.CD003474.pub2-BIB54|cit54","doi-asserted-by":"crossref","first-page":"3890","DOI":"10.1200\/JCO.1998.16.12.3890","article-title":"Current use of bisphosphonates in oncology","volume":"16","author":"Body","year":"1998","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD003474.pub2-BIB55|cit55","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/0305-7372(85)90008-8","article-title":"Bone metastases and breast cancer","volume":"12","author":"Coleman","year":"1985","journal-title":"Cancer Treatment Reviews"},{"issue":"1","key":"10.1002\/14651858.CD003474.pub2-BIB56|cit56","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/bjc.1987.13","article-title":"The clinical course of bone metastases from breast cancer","volume":"55","author":"Coleman","year":"1987","journal-title":"British Journal of Cancer"},{"issue":"23","key":"10.1002\/14651858.CD003474.pub2-BIB57|cit57","doi-asserted-by":"crossref","first-page":"3925","DOI":"10.1200\/JCO.2000.18.23.3925","article-title":"Identifying breast cancer patients at high risk for bone metastases","volume":"18","author":"Colleoni","year":"2000","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD003474.pub2-BIB58|cit58","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1093\/jnci\/93.7.534","article-title":"Methodology for treatment evaluation in patients with cancer metastatic to bone","volume":"93","author":"Cook","year":"2001","journal-title":"Journal National Cancer Institute"},{"issue":"8","key":"10.1002\/14651858.CD003474.pub2-BIB59|cit59","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1002\/(SICI)1097-0142(19971015)80:8+<1646::AID-CNCR14>3.0.CO;2-#","article-title":"Issue concerning the role of chemotherapy and hormonal therapy of bone metastases from breast cancer","volume":"80","author":"Harvey","year":"1997","journal-title":"Cancer"},{"issue":"2 Suppl","key":"10.1002\/14651858.CD003474.pub2-BIB60|cit60","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/8756-3282(95)00194-I","article-title":"Bone and cancer: pathophysiology and treatment of metastases","volume":"17","author":"Kanis","year":"1995","journal-title":"Bone"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD003474.pub2-BIB61|cit61","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/8756-3282(91)90057-P","article-title":"Mechanisms of osteolytic bone destruction","volume":"12","author":"Mundy","year":"1991","journal-title":"Bone"},{"issue":"8","key":"10.1002\/14651858.CD003474.pub2-BIB62|cit62","first-page":"1546","article-title":"Mechanisms of bone metastases","volume":"80","author":"Mundy","year":"1987","journal-title":"Cancer"},{"issue":"8","key":"10.1002\/14651858.CD003474.pub2-BIB63|cit63","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1002\/(SICI)1097-0142(19971015)80:8+<1652::AID-CNCR15>3.0.CO;2-Z","article-title":"Overview of bisphosphonates","volume":"80","author":"Rogers","year":"1997","journal-title":"Cancer"},{"issue":"5","key":"10.1002\/14651858.CD003474.pub2-BIB64|cit64","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.joms.2004.02.004","article-title":"Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases","volume":"62","author":"Ruggiero","year":"2004","journal-title":"Journal Oral and Maxillofacial Surgery"},{"issue":"1","key":"10.1002\/14651858.CD003474.pub2-BIB65|cit65","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/S8756-3282(99)00116-7","article-title":"Bisphosphonates: from the laboratory to the clinic and back again","volume":"25","author":"Russell","year":"1999","journal-title":"Bone"},{"key":"10.1002\/14651858.CD003474.pub2-BIB66|cit66","doi-asserted-by":"crossref","first-page":"2589","DOI":"10.1002\/1097-0142(19861215)58:12<2589::AID-CNCR2820581206>3.0.CO;2-O","article-title":"Clinical course of breast cancer patients with osseous metastases treated with combination chemotherapy","volume":"58","author":"Scheid","year":"1986","journal-title":"Cancer"},{"key":"10.1002\/14651858.CD003474.pub2-BIB67|cit67","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1053\/ctrv.1999.0161","article-title":"Systematic reviews of chemotherapy and endocrine therapy in metastatic breast cancer","volume":"26","author":"Stockler","year":"2000","journal-title":"Cancer Treatment Reviews"},{"key":"10.1002\/14651858.CD003474.pub2-BIB68|cit68","unstructured":"World Health Organisation World Cancer Report The International Agency for Research on Cancer 2003"},{"key":"10.1002\/14651858.CD003474.pub2-BIB69|cit69","doi-asserted-by":"crossref","first-page":"753","DOI":"10.7326\/0003-4819-144-10-200605160-00009","article-title":"Systematic Review: Bisphosphonates and Osteonecrosis of the Jaws","volume":"144","author":"Sook-Bin","year":"2006","journal-title":"Annals of Internal Medicine"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cochranelibrary.com\/cdsr\/doi\/10.1002\/14651858.CD003474.pub2\/epdf\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,9]],"date-time":"2021-08-09T21:21:11Z","timestamp":1628544071000},"score":1,"resource":{"primary":{"URL":"https:\/\/doi.wiley.com\/10.1002\/14651858.CD003474.pub2"}},"subtitle":[],"editor":[{"given":"Nick","family":"Pavlakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2005,7,20]]},"references-count":69,"URL":"https:\/\/doi.org\/10.1002\/14651858.cd003474.pub2","relation":{},"subject":[],"published":{"date-parts":[[2005,7,20]]}}}